drugs for the treatment and prevention of …rajatanavin r. effect of alendronate on bone mineral...
TRANSCRIPT
1
Drugs for the Treatment and Prevention of Osteoporosis in Postmenopausal Women
List of Included Studies (main publications) 1. Adami S, Bruni V, Bianchini D, et al. Prevention of early postmenopausal bone loss with cyclical
etidronate. J Endocrinol Invest. 2000;23(5):310-316. 2. Adami S, Passeri M, Ortolani S, et al. Effects of oral alendronate and intranasal salmon calcitonin
on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis. Bone. 1995;17(4):383-390.
3. Aki S, Gulbaba RG, Eskiyurt N. Effect of alendronate on bone density and bone markers in postmenopausal osteoporosis. J Back Musculoskelet Rehabil. 2004;17(1):27-31.
4. Akyol Y, Tander B, Alayli G, Durmus D, Bek Y, Canturk F. The comparison of effectiveness of alendronate and risedronate in osteoporosis treatment. Turkiye Fiziksel Tip ve Rehabilitasyon Dergisi. 2006;52(3):110-114.
5. Anastasilakis AD, Polyzos SA, Gkiomisi A, Bisbinas I, Gerou S, Makras P. Comparative effect of zoledronic acid versus denosumab on serum sclerostin and Dickkopf-1 levels of naive postmenopausal women with low bone mass: a randomized, head-to-head clinical trial. J Clin Endocrinol Metab. 2013;98(8):3206-3212.
6. Anastasilakis AD, Polyzos SA, Gkiomisi A, et al. Denosumab versus zoledronic acid in patients previously treated with zoledronic acid. Osteoporos Int. 2015;26:2521-2527.
7. Aro E, Moritz N, Mattila K, Aro HT. A long-lasting bisphosphonate partially protects periprosthetic bone, but does not enhance initial stability of uncemented femoral stems: A randomized placebo-controlled trial of women undergoing total hip arthroplasty. J Biomech. 2018;75:35-45.
8. Aro HT. Denosumab in prevention of periprosthetic bone loss in cementless hip replacement of postmenopausal women. Osteoporos Int. 2018(Supplement 1):S131.
9. Ascott-Evans BH, Guanabens N, Kivinen S, et al. Alendronate prevents loss of bone density associated with discontinuation of hormone replacement therapy: A randomized controlled trial. Arch Intern Med. 2003;163(7):789-794.
10. Atmaca A, Gedik O. Effects of alendronate and risedronate on bone mineral density and bone turnover markers in late postmenopausal women with osteoporosis. Adv Ther. 2006;23(6):842-853.
11. Bai H, Jing D, Guo A, Yin S. Randomized controlled trial of zoledronic acid for treatment of osteoporosis in women. J Int Med Res. 2013;41(3):697-704.
12. Bala Y, Chapurlat R, Cheung AM, et al. Risedronate slows or partly reverses cortical and trabecular microarchitectural deterioration in postmenopausal women. J Bone Miner Res. 2014;29(2):380-388.
13. Bell NH, Bilezikian JP, Bone HG, Kaur A, Maragoto A, Santora AC. Alendronate increases bone mass and reduces bone markers in postmenopausal African-American women. J Clin Endocrinol Metab. 2002;87(6):2792-2797.
14. Benhamou CL, Seefried L, Agodoa I, et al. Treatment satisfaction in postmenopausal women suboptimally adherent to alendronate who transitioned to denosumab vs risedronate. Osteoporos Int. 2013;24(Suppl 1):S159-S160.
15. Bilek LD, Waltman NL, Lappe JM, et al. Protocol for a randomized controlled trial to compare bone-loading exercises with risedronate for preventing bone loss in osteopenic postmenopausal women. BMC Womens Health. 2016;16:59, 2016.
16. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 1996;348(9041):1535-1541.
17. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356(18):1809-1822.
18. Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med. 2003;349(13):1207-1215.
2
19. Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: The Fracture Intervention Trial long-term extension (FLEX): A randomized trial. JAMA. 2006;296(24):2927-2938.
20. Bone HG, Bolognese M, Yuen CK, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab. 2008;93(6):2149-2157.
21. Bone HG, Downs RW, Tucci JR, et al. Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers. J Clin Endocrinol Metab. 1997;82(1):265-274.
22. Bone HG, Greenspan SL, McKeever C, et al. Alendronate and estrogen effects in postmenopausal women with low bone mineral density. J Clin Endocrinol Metab. 2000;85(2):720-726.
23. Bonnick S, Broy S, Kaiser F, et al. Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density. Curr Med Res Opin. 2007;23(6):1341-1349.
24. Boutsen Y, Jamart J, Vynckier C, Borght TV, Devogelaer JP. Prevention of postmenopausal osteoporosis with two intermittent alendronate regimens: Bone mineral density and bone markers changes after 24 months. J Bone Miner Res. 2012;27(Suppl 1).
25. Boyd SK, Nishiyama KK, Zebaze RM, et al. Denosumab decreases cortical porosity in postmenopausal women with low BMD. Endocr Rev. 2011;32(3):S182.
26. Brown JP, Kendler DL, McClung MR, et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int. 2002;71:103-111.
27. Brown JP, Prince RL, Deal C, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: A randomized, blinded, phase 3 trial. J Bone Miner Res. 2009;24(1):153-161.
28. Burghardt AJ, Kazakia GJ, Sode M, e Papp AE, Link TM, Majumdar S. A longitudinal HR-pQCT study of alendronate treatment in postmenopausal women with low bone density: Relations among density, cortical and trabecular microarchitecture, biomechanics, and bone turnover. J Bone Miner Res. 2010;25(12):2558-2571.
29. Catalano A, Morabito N, Atteritano M, Basile G, Cucinotta D, Lasco A. Vitamin D reduces musculoskeletal pain after infusion of zoledronic acid for postmenopausal osteoporosis. Calcif Tissue Int. 2012;90(4):279-285.
30. Catalano A, Morabito N, Basile G, Brancatelli S, Cucinotta D, Lasco A. Zoledronic acid acutely increases sclerostin serum levels in women with postmenopausal osteoporosis. J Clin Endocrinol Metab. 2013;98(5):1911-1915.
31. Cecelja M, Edwards S, Moore A, Fogelman I, Chowienczyk P, Frost M. A pilot study to assess effects of alendronic acid on aortic calcification and stiffness in postmenopausal women. J Hypertens. 2015;33:e347.
32. Chailurkit LO, Jongjaroenprasert W, Rungbunnapun S, Ongphiphadhanakul B, Sae-Tung S, Rajatanavin R. Effect of alendronate on bone mineral density and bone turnover in Thai postmenopausal osteoporosis. J Bone Miner Metab. 2003;21(6):421-427.
33. Chao M, Hua Q, Yingfeng Z, et al. Study on the role of zoledronic acid in treatment of postmenopausal osteoporosis women. Pakistan Journal of Medical Sciences 2013;29(6):1381-1384.
34. Chavez-Valencia V, Arce-Salinas CA, Espinosa-Ortega F. Cost-minimization study comparing annual infusion of zoledronic acid or weekly oral alendronate in women with low bone mineral density. J Clin Densitom. 2014;17(4):484-489.
35. Cheng ZQ, Yin W, Fan JY, Ma TJ. [The efficacy of alendronate in the prevention and treatment of postmenopausal osteoporosis]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2002;24(3):306-309.
36. Chesnut CH, McClung MR, Ensrud KE, et al. Alendronate treatment of the postmenopausal osteoporotic woman: Effect of multiple dosages on bone mass and bone remodeling. Am J Med. 1995;99(2):144-152.
37. Chilibeck PD, Davison KS, Whiting SJ, Suzuki Y, Janzen CL, Peloso P. The effect of strength training combined with bisphosphonate (etidronate) therapy on bone mineral, lean tissue, and fat mass in postmenopausal women. Can J Physiol Pharmacol. 2002;80(10):941-950.
3
38. Clemente PA, Cardama F, Armengol R, Goma MT. [ Effect of therapeutical association between hormone replacement therapy and cyclic intermittent therapy with etidronate about bone mineral content in women with postmenopausal osteoporosis. ]. ProgrObstet Ginecol. 1996;39:593-597.
39. Clemmesen B, Ravn P, Zegels B, Taquet AN, Christiansen C, Reginster JY. A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis. Osteoporos Int. 1997;7(5):488-495.
40. Cosman F, Eriksen EF, Recknor C, et al. Effects of intravenous zoledronic acid plus subcutaneous teriparatide in postmenopausal osteoporosis. J Bone Miner Res. 2011;26(3):503-511.
41. Cosman F, Gilchrist N, McClung M, et al. A phase 2 study of MK-5442, a calcium-sensing receptor antagonist, in postmenopausal women with osteoporosis after long-term use of oral bisphosphonates. Osteoporos Int. 2016;27(1):377-386.
42. Cosman F, Keaveny TM, Kopperdahl D, et al. Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene. J Bone Miner Res. 2013;28(6):1328-1336.
43. Creatsa M, Pliatsika P, Kaparos G, et al. The effect of vitamin D receptor BsmI genotype on the response to osteoporosis treatment in postmenopausal women: a pilot study. J Obstet Gynaecol Res. 2011;37(10):1415-1422.
44. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. Results from the Fracture Intervention Trial. JAMA. 1998;280(24):2077-2082.
45. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756-765.
46. D'Amelio P, Grimaldi A, Cristofaro MA, et al. Alendronate reduces osteoclast precursors in osteoporosis. Osteoporos Int. 2010;21(10):1741-1750.
47. Davas I, Altintas A, Yoldemir T, Varolan A, Yazgan A, Baksu B. Effect of daily hormone therapy and alendronate use on bone mineral density in postmenopausal women. Fertil Steril. 2003;80(3):536-540.
48. de Villiers T, Benhamou C, Conrad JC, et al. Resolution of effects on bone turnover markers and BMD after discontinuation of long-term bisphosphonate use. Osteoporos Int. 2013;24(Suppl 1):S138.
49. Delmas PD, Benhamou CL, Man Z, et al. Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results. Osteoporos Int. 2008;19(7):1039-1045.
50. Delmas PD, McClung MR, Zanchetta JR, et al. Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. Bone. 2008;42(1):36-42.
51. Devogelaer JP, Brown JP, Burckhardt P, et al. Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis. Osteoporos Int. 2007;18(9):1211-1218.
52. Dobnig H, Hofbauer LC, Viereck V, Obermayer-Pietsch B, Fahrleitner-Pammer A. Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients. Osteoporos Int. 2006;17(5):693-703.
53. Dogan B, Guzel R, Adam M, Sarpel T, Goncu MK. Comparison of different therapeutic regimens in the treatment of patients with post menopausal osteoporosis. Journal of Rheumatology and Medical Rehabilitation. 2001;12(3):143-147.
54. Downs J, Bell NH, Ettinger MP, et al. Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women. J Clin Endocrinol Metab. 2000;85(5):1783-1788.
55. Dundar U, Kavuncu V, Ciftci IH, Evcik D, Solak O, Cakir T. The effect of risedronate treatment on serum cytokines in postmenopausal osteoporosis: a 6-month randomized and controlled study. J Bone Miner Metab. 2009;27(4):464-470.
56. Dursun N, Dursun E, Yalcin S. Comparison of alendronate, calcitonin and calcium treatments in postmenopausal osteoporosis. Int J Clin Pract. 2001;55(8):505-509.
57. Eastell R, Nagase S, Ohyama M, et al. Safety and efficacy of the cathepsin K inhibitor ONO-5334 in postmenopausal osteoporosis: The OCEAN study. J Bone Miner Res. 2011;26(6):1303-1312.
58. Evans RA, Somers NM, Dunstan CR, Royle H, Kos S. The effect of low-dose cyclical etidronate and calcium on bone mass in early postmenopausal women. Osteoporos Int. 1993;3(2):71-75.
4
59. Felsenberg D, Charpulat R, Cheung AM, et al. Longitudinal in vivo micro-CT assessment in osteopenic women demonstrated that risedronate reduced the deterioration of cortical bone. Bone. 2010:S35.
60. Finkelstein JS, Wyland JJ, Lee H, Neer RM. Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. J Clin Endocrinol Metab. 2010;95(4):1838-1845.
61. Fogelman I, Ribot C, Smith R, Ethgen D, Sod E, Reginster JY. Risedronate reverses bone loss in postmenopausal women with low bone mass: Results from a multinational, double-blind, placebo-controlled trial. J Clin Endocrinol Metab. 2000;85(5):1895-1900.
62. Folkesson J, Goldenstein J, Carballido-Gamio J, et al. Longitudinal evaluation of the effects of alendronate on MRI bone microarchitecture in postmenopausal osteopenic women. Bone. 2011;48:611-621.
63. Frediani B, Allegri A, Bisogno S, Marcolongo R. Effects of combined treatment with calcitriol plus alendronate on bone mass and bone turnover in postmenopausal osteoporosis: Two years of continuous treatment. Clin Drug Investig. 1998;15:235-244.
64. Freemantle N, Satram-Hoang S, Tang ET, et al. Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int. 2012;23(1):317-326.
65. Fukunaga M, Kushida K, Kishimoto H, et al. A Comparison of the Effect of Risedronate and Etidronate on Lumbar Bone Mineral Density in Japanese Patients with Osteoporosis: A Randomized Controlled Trial. Osteoporos Int. 2002;13(12):971–979.
66. Galesanu C. Biological therapy or bisphosphonates in postmenopausal women with osteoporosis? Calcif Tissue Int. 2018(Supplement 1):S137.
67. Galesanu C, Gheorghe L, Lisnic N, Zaharia V. Denosumab vs. zoledronic acid in treatment of osteoporosis in postmeno-pausal women. Osteoporos Int. 2017:S295.
68. Galesanu C, Lisnic N, Mocanu V, Florescu A, Loghin AI, Galesanu MR. Efficacy of bisphosphonates in the treatment of postmenopausal osteoporosis. Osteoporos Int. 2011:S739.
69. Galesanu C, Lisnic N, Moisii L. Denosumab significantly increases BMD compared with alendronate in postmenopausal women. Osteoporos Int. 2015:S150.
70. Gonnelli S, Cepollaro C, Montagnani A, et al. Heel ultrasonography in monitoring alendronate therapy: a four-year longitudinal study. Osteoporos Int. 2002;13(5):415-421.
71. Gonnelli S, Cepollaro C, Pondrelli C, et al. Bone turnover and the response to alendronate treatment in postmenopausal osteoporosis. Calcif Tissue Int. 1999;65(5):359-364.
72. Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB. Early changes in biochemical markers of bone turnover predict the long- term response to alendronate therapy in representative elderly women: A randomized clinical trial. J Bone Miner Res. 1998;13:1431-1438.
73. Greenspan SL, Resnick NM, Parker RA. Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial. JAMA. 2003;289:2525-2533.
74. Greenspan SL, Schneider DL, McClung MR, et al. Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2002;136:742-746.
75. Grey A, Bolland M, Wattie D, Horne A, Gamble G, Reid IR. Prolonged antiresorptive activity of zoledronate: A randomized, controlled trial. J Bone Miner Res. 2010;25:2251-2255.
76. Grey A, Bolland M, Wong S, Horne A, Gamble G, Reid IR. Low-dose zoledronate in osteopenic postmenopausal women: a randomized controlled trial. J Clin Endocrinol Metab. 2012;97:286-292.
77. Grey A, Bolland MJ, Horne A, et al. Five years of anti-resorptive activity after a single dose of zoledronate--results from a randomized double-blind placebo-controlled trial. Bone. 2012;50:1389-1393.
78. Gu JM, Wang L, Lin H, et al. The efficacy and safety of weekly 35-mg risedronate dosing regimen for Chinese postmenopausal women with osteoporosis or osteopenia: 1-year data. Chung Kuo Yao Li Hsueh Pao. 2015;36:841-846.
5
79. Gurlek A, Bayraktar M, Gedik O. Comparison of calcitriol treatment with etidronate-calcitriol and calcitonin-calcitriol combinations in Turkish women with postmenopausal osteoporosis: A prospective study. Calcif Tissue Int. 1997;61:39-43.
80. Hadji P, Gamerdinger D, Spieler W, et al. Rapid Onset and Sustained Efficacy (ROSE) study: results of a randomised, multicentre trial comparing the effect of zoledronic acid or alendronate on bone metabolism in postmenopausal women with low bone mass. Osteoporos Int. 2012;23:625-633.
81. Hagino H, Nishizawa Y, Sone T, et al. A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis. Bone. 2009;44:1078-1084.
82. Han LW, Ma DD, Xu XJ, et al. Association Between Geranylgeranyl Pyrophosphate Synthase Gene Polymorphisms and Bone Phenotypes and Response to Alendronate Treatment in Chinese Osteoporotic Women. Chin Med Sci J. 2016;31:8-16.
83. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA. 1999;282:1344-1352.
84. Hasling C, Charles P, Jensen FT, Mosekilde L. A comparison of the effects of oestrogen/progestogen, high-dose oral calcium, intermittent cyclic etidronate and an ADFR regime on calcium kinetics and bone mass in postmenopausal women with spinal osteoporosis. Osteoporos Int. 1994;4:191-203.
85. Heath DA, Bullivant BG, Boiven C, Balena R. The effects of cyclical etidronate on early postmenopausal bone loss: An open, randomized controlled study. J Clin Densitom. 2000;3(1):27-33.
86. Herd RJM, Balena R, Blake GM, Ryan PJ, Fogelman I. The prevention of early postmenopausal bone loss by cyclical etidronate therapy: A 2-year, double-blind, placebo-controlled study. Am J Med. 1997;103:92-99.
87. Ho AYY, Kung AWC. Efficacy and tolerability of alendronate once weekly in Asian postmenopausal osteoporotic women. Ann Pharmacother. 2005;39:1428-1433.
88. Hooper MJ, Ebeling PR, Roberts AP, et al. Risedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebo-controlled trial. Climacteric : the journal of the International Menopause Society. 2005;8:251-262.
89. Hosking D, Chilvers CED, Christiansen C, et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. N Engl J Med. 1998;338:485-492.
90. Hu YF, Sun ZQ. Quality of life in the treatment assessment of postmenopausal osteoporosis. Journal of Central South University (Medical Sciences). 2005;30:299-303.
91. Hyuk J, Lee BI. Combination therapy with raloxifene and alendronate for treatment of osteoporosis in elderly women. Maturitas. 2017:155.
92. Invernizzi M, Carda S, Baricich A, Cisari C. Preliminary results of a randomized head to head study between denosumab and zoledronic acid in severe osteoporotic women. J Bone Miner Res. 2013.
93. Ishida Y, Kawai S. Comparative efficacy of hormone replacement therapy, etidronate, calcitonin, alfacalcidol, and vitamin K in postmenopausal women with osteoporosis: The Yamaguchi Osteoporosis Prevention Study. Am J Med. 2004;117(8):549-555.
94. Iwamoto J, Takeda T, Sato Y, Uzawa M. Comparison of effect of treatment with etidronate and alendronate on lumbar bone mineral density in elderly women with osteoporosis. Yonsei Med J. 2005;46:750-758.
95. Johnell O, Scheele WH, Lu Y, Reginster JY, Need AG, Seeman E. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2002;87:985-992.
96. Kendler DL, Gold DT, Horne R, et al. Assessment of preference and satisfaction with a weekly oral tablet versus a 6-month subcutaneous injection for the treatment of osteoporosis. Value Health. 2009;12:A16.
97. Kendler DL, Roux C, Benhamou CL, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res. 2010;25:72-81.
6
98. Khanizadeh FR, Rahmani A, Asadollahi K, Ahmadi MR, H. Combination therapy of curcumin and alendronate modulates bone turnover markers and enhances bone mineral density in postmenopausal women with osteoporosis. Archives of Endocrinology and Metabolism. 2018;62(4):438-445.
99. Kosus A, Capar M, Kosus N. Cyclical alendronate treatment in postmenopausal women with osteoporosis. International Journal of Gynecology and Obstetrics. 2005;91:182-184.
100. Kume K, Amano K, Yamada S, Nagata H. Change in bone mineral density of osteoporosis with postmenopausal woman older than 85 years of age treated with bisphophonates. A prospective open label study. Intern Med J. 2009:A67.
101. Kung AWC, Yeung SSC, Chu LW. The efficacy and tolerability of alendronate in postmenopausal osteoporotic Chinese women: A randomized placebo-controlled study. Calcif Tissue Int. 2000;67:286-290.
102. Kushida K, Shiraki M, Nakamura T, et al. The efficacy of alendronate in reducing the risk for vertebral fracture in Japanese patients with osteoporosis: a randomized, double-blind, active-controlled, double-dummy trial. Current Therapeutic Research. 2002;63(9):606-620.
103. Lau EMC, Woo J, Chan YH, Griffith J. Alendronate prevents bone loss in Chinese women with osteoporosis. Bone. 2000;27:677-680.
104. Leung JY, Ho AY, Ip TP, Lee G, Kung AW. The efficacy and tolerability of risedronate on bone mineral density and bone turnover markers in osteoporotic Chinese women: a randomized placebo-controlled study. Bone. 2005;36:358-364.
105. Leung PC, Qin L, Au SK. Prevention of osteoporotic fractures among high-risk groups of post-menopausal women. Hong Kong Med J. 2006;12:36-39.
106. Lewiecki EM, Miller PD, McClung MR, et al. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res. 2007;22:1832-1841.
107. Li M, Zhang ZL, Liao EY, et al. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis. Menopause. 2013;20(1):72-78.
108. Li Y, Zhang Z, Deng X, Chen L. Efficacy and safety of risedronate sodium in treatment of postmenopausal osteoporosis. Journal of Huazhong University of Science and Technology. 2005;Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban. 25:527-529.
109. Liang BC, Shi ZY, Wang B, et al. Intravenous Zoledronic Acid 5 mg on Bone Turnover Markers and Bone Mineral Density in East China Subjects with Newly Diagnosed Osteoporosis: A 24-month Clinical Study. Orthop Surg. 2017;9:103-109.
110. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med. 1995;333:1437-1443.
111. Lin H, Xu T, Fan L, Yang H, Chen X. Effect ofa once-yearly zoledronic acid on BMD and the risk of falling in postmenopausalwomenwithosteoporosis. Osteoporos Int. 2011:S649-S650.
112. Ling Q, Wingyee C, Szeki A, Musei F, Pingchung L. Alendronate increases BMD at appendicular and axial skeletons in patients with established osteoporosis. J Orthop Surg Res. 2007;2:9.
113. Liu Y, Liu H, Li M, et al. Association of farnesyl diphosphate synthase polymorphisms and response to alendronate treatment in Chinese postmenopausal women with osteoporosis. Chin Med J. 2014;127:662-668.
114. Luckey MM, Gilchrist N, Bone HG, et al. Therapeutic equivalence of alendronate 35 milligrams once weekly and 5 milligrams daily in the prevention of postmenopausal osteoporosis. Obstet Gynecol. 2003;101:711-721.
115. Lyritis GP, Tsakalakos N, Paspati I, Skarantavos G, Galanos A, Androulakis C. The effect of a modified etidronate cyclical regimen on postmenopausal osteoporosis: a four-year study. Clin Rheumatol. 1997;16:354-360.
116. McClung M, Clemmesen B, Daifotis A, et al. Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group. Ann Intern Med. 1998;128:253-261.
7
117. McClung M, Miller P, Recknor C, Mesenbrink P, Bucci-Rechtweg C, Benhamou CL. Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: A randomized controlled trial. Obstet Gynecol. 2009;114:999-1007.
118. McClung M, Recker R, Miller P, et al. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone. 2007;41:122-128.
119. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. The New England Journal of Medicine. 2001;344:333-340.
120. McClung MR, Grauer A, Boonen S, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014;370:412-420.
121. McClung MR, Miller PD, Brown JP, et al. Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet. Osteoporos Int. 2012;23:267-276.
122. Meunier PJ, Confavreux E, Tupinon I, Hardouin C, Delmas PD, Balena R. Prevention of early postmenopausal bone loss with cyclical etidronate therapy (a double-blind, placebo-controlled study and 1-year follow-up). J Clin Endocrinol Metab. 1997;82:2784-2791.
123. Michalska D, Stepan JJ, Basson BR, Pavo I. The effect of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab. 2006;91:870-877.
124. Miller PD, Pannacciulli N, Brown JP, et al. Denosumab treatment is associated with greater transient increases in serum intact parathyroid hormone concentrations compared with zoledronic acid: Results from a study in postmenopausal women with osteoporosis previously treated with oral bisphosphonates. Endocr Rev. 2016.
125. Miller PD, Pannacciulli N, Brown JP, et al. Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates. J Clin Endocrinol Metab. 2016;101:3163-3170.
126. Montessori MLM, Scheele WH, Netelenbos JC, Kerkhoff JF, Bakker K. The use of etidronate and calcium versus calcium alone in the treatment of postmenopausal osteopenia: Results of three years of treatment. Osteoporos Int. 1997;7:52-58.
127. Mortensen L, Charles P, Bekker PJ, Digennaro J, Johnston CC. Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up. The Journal of clinical endocrinology and metabolism. 1998;83:396-402.
128. Nakamura T, Matsumoto T, Sugimoto T, et al. Clinical Trials Express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT). J Clin Endocrinol Metab. 2014;99:2599-2607.
129. Nakamura T, Matsumoto T, Sugimoto T, Shiraki M. Dose-response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis. Osteoporos Int. 2012;23(3):1131-1140.
130. Nenonen A, Cheng S, Ivaska KK, et al. Serum TRACP 5b is a useful marker for monitoring alendronate treatment: Comparison with other markers of bone turnover. J Bone Miner Res. 2005;20:1804-1812.
131. Nieves J, Cosman F, Boutroy S, et al. Teriparatide treatment for 24 months in postmenopausal women with osteoporosis differentially impacts cortical and trabecular bone at the tibia assessedby HRpQCT. J Bone Miner Res. 2011.
132. Ohtori S, Inoue G, Orita S, et al. Comparison of teriparatide and bisphosphonate treatment to reduce pedicle screw loosening after lumbar spinal fusion surgery in postmenopausal women with osteoporosis from a bone quality perspective. Spine (Phila Pa 1976). 2013;38:E487-E492.
133. Okamoto K, Inaba M, Furumitsu Y, et al. Beneficial effect of risedronate on arterial thickening and stiffening with a reciprocal relationship to its effect on bone mass in female osteoporosis patients: a longitudinal study. Life Sci. 2010;87:686-691.
134. Pacifici R, McMurtry C, Vered I, Rupich R, Avioli LV. Coherence Therapy Does Not Prevent Axial Bone Loss in Osteoporotic Women: A Preliminary Comparative Study. J Clin Endocrinol Metab. 1988;66(4):747-753.
8
135. Paggiosi MA, Peel N, McCloskey E, Walsh JS, Eastell R. Comparison of the effects of three oral bisphosphonate therapies on the peripheral skeleton in postmenopausal osteoporosis: the TRIO study. Osteoporos Int. 2014;25:2729-2741.
136. Passeri M, Baroni MC, Pedrazzoni M, et al. Intermittent treatment with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate (AHBuBP) in the therapy of postmenopausal osteoporosis. Bone Miner. 1991;15:237-247.
137. Pastore R, Bultrini A, Di GP, Cannuccia A, Frontoni S. Sequentialtherapy in severe osteoporosis. Osteoporos Int. 2014:S254.
138. Pols HAP, Felsenberg D, Hanley DA, et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: Results of the FOSIT study. Osteoporos Int. 1999;9:461-468.
139. Pouilles JM, Tremollieres F, Roux C, et al. Effects of cyclical etidronate therapy on bone loss in early postmenopausal women who are not undergoing hormonal replacement therapy. Osteoporos Int. 1997;7:213-218.
140. Recker R, Valter I, Maasalu K, et al. Bone safety of a novel delayed-release risedronate 35 mg once-a-week assessed by bone histology and histomorphometry. J Bone Miner Res. 2011.
141. Reid DM, Hosking D, Kendler D, et al. A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-Month results from FACTS-International. Int J Clin Pract. 2008;62:575-584.
142. Reid IR, Bolland M, Wong S, Horne A, Gamble G, Grey A. A randomized controlled trial ofannual low dose zoledronate in postmenopausal women. Osteoporos Int. 2011:S526.
143. Reid IR, Horne AM, Mihov B, et al. Fracture Prevention with Zoledronate in Older Women with Osteopenia. N Engl J Med. 2018;379(25):2407-2416.
144. Robles-Carranza LP, Chavez-Valencia V, Arce-Salinas CA. Comparison of the efficacy of annual zoledronic acid or weekly alendronate. A 3-yr analysis of postmenopausal women with low bone mineral density. Annals of the Rheumatic Disease. 2013.
145. Rossini M, Gatti D, Girardello S, Braga V, James G, Adami S. Effects of two intermittent alendronate regimens in the prevention or treatment of postmenopausal osteoporosis. Bone. 2000;27:119-122.
146. Roux C, Hofbauer LC, Ho PR, et al. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study. Bone. 2014;58:48-54.
147. Russo MS, Panebianco P, Di SF, et al. The use of bisphosphonates in the treatment of osteoporosis. Arch Gerontol Geriatr. 1996;23:551-555.
148. Saag KG, Benhamou CL, Villiers TD, et al. Resolution of effects on bone turnover markers and bone mineral density after discontinuation of long-term bisphosphonate use. Arthritis Rheum. 2012:S835-S836.
149. Sahota O, Fowler I, Blackwell PJ, et al. A comparison of continuous alendronate, cyclical alendronate and cyclical etidronate with calcitriol in the treatment of postmenopausal vertebral osteoporosis: A randomized controlled trial. Osteoporos Int. 2000;11:959-966.
150. Sambrook PN, Rodriguez JP, Wasnich RD, et al. Alendronate in the prevention of osteoporosis: 7-year follow-up. Osteoporos Int. 2004;15:483-488.
151. Sarioglu M, Tuzun C, Unlu Z, Tikiz C, Taneli F, Uyanik BS. Comparison of the effects of alendronate and risedronate on bone mineral density and bone turnover markers in postmenopausal osteoporosis. Rheumatol Int. 2006;26:195-200.
152. Schnitzer T, Bone HG, Crepaldi G, et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging - Clinical and Experimental Research. 2000;12:1-12.
153. Seeman E, Borah B, Chapurlat R, Felsenberg D, Darbie L, Rizzoli R. Risedronate reduces deterioration of cortical bone microarchitecture accompanying menopause. J Bone Miner Res. 2010:S32.
154. Seeman E, Delmas PD, Hanley DA, et al. Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res. 2010;25:1886-1894.
9
155. Shilbayeh S, Zumeili A, Hilow HM. The efficacy and safety of Calidron tablets for management of osteoporosis in Jordanian women: A randomised clinical trial. Saudi Pharmaceutical Journal. 2004;12:86-95.
156. Shiota E, Tsuchiya K, Yamaoka K, Kawano O. Effect of intermittent cyclical treatment with etidronate disodium (HEBP) and calcium plus alphacalcidol in postmenopausal osteoporosis. J Orthop Sci. 2001;6:133-136.
157. Steiniche T, Hasling C, Charles P, Eriksen EF, Melsen F, Mosekilde L. The effects of etidronate on trabecular bone remodeling in postmenopausal spinal osteoporosis: A randomized study comparing intermittent treatment and an ADFR regime. Bone. 1991;12:155-163.
158. Ste-Marie LG, Schwartz SL, Hossain A, Desaiah D, Gaich GA. Effect of teriparatide [rhPTH(1-34)] on BMD when given to postmenopausal women receiving hormone replacement therapy. J Bone Miner Res. 2006;21(2):283-291.
159. Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OH. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women postmenopausal osteoporosis. N Engl J Med. 1990;322:1265-1271.
160. Suzuki T, Nakamura Y, Tanaka M, et al. Comparison of the effects of denosumab with either active vitamin D or native vitamin D on bone mineral density and bone turnover markers in postmenopausal osteoporosis. Mod Rheumatol. 2018;28(2):376-379.
161. Tan W, Sun J, Zhou L, Li Y, Wu X. Randomized trial comparing efficacies of zoledronate and alendronate for improving bone mineral density and inhibiting bone remodelling in women with post-menopausal osteoporosis. J Clin Pharm Ther. 2016;41(5):519-523.
162. Tira MB, Noyan V, Yildiz A, Yildirim M, Daya S. Effects of alendronate and hormone replacement therapy, alone or in combination, on bone mass in postmenopausal women with osteoporosis: A prospective, randomized study. Hum Reprod. 2000;15:2087-2092.
163. Tobias JH, Dalzell N, Pazianas M, Chambers TJ. Cyclical etidronate prevents spinal bone loss in early post-menopausal women. Br J Rheumatol. 1997;36:612-613.
164. Tutuncu L, Arslanhan N, Mungen E, Yilmaz S, Yergok YZ. Combined usage of raloxifene and alendronate: Effects on biochemical markers. Nobel Medicus. 2005;1:12-19.
165. Um MJ, Cho EA, Jung H. Combination Therapy of Raloxifene and Alendronate for Treatment of Osteoporosis in Elderly Women. J Menopausal Med. 2017;23:56-62.
166. Uusi-Rasi K, Kannus P, Cheng S, et al. Effect of alendronate and exercise on bone and physical performance of postmenopausal women: A randomized controlled trial. Bone. 2003;33(1):132-143.
167. Valimaki MJ, Farrerons-Minguella J, Halse J, et al. Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial. Clin Ther. 2007;29(9):1937-1949.
168. Vilariño SIA, Vilarino C, Schwartz A, Contreras Ortiz O, Dotto J. Comparison of different treatments on postmenopausal patients (POSTM). Maturitas. 2009;63(Suppl 1):S95.
169. Watts NB, Harris ST, Genant HK, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med. 1990;323(2):73-79.
170. Wimalawansa SJ. Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: Four-year randomized study. Am J Med. 1995;99(3):36-42.
171. Yamaguchi K, Masuhara K, Yamasaki S, Fuji T. Efficacy of different dosing schedules of etidronate for stress shielding after cementless total hip arthroplasty. J Orthop Sci. 2005;10(1):32-36.
172. Yan Y, Wang W, Zhu H, et al. The efficacy and tolerability of once-weekly alendronate 70 mg on bone mineral density and bone turnover markers in postmenopausal Chinese women with osteoporosis. J Bone Miner Metab. 2009;27(4):471-478.
173. Yang Y, Luo X, Yan F, et al. Effect of zoledronic acid on vertebral marrow adiposity in postmenopausal osteoporosis assessed by MR spectroscopy. Skeletal Radiol. 2015;44(10):1499-1505.
174. Yanik B, Kulcu DG. The effect of raloxifene, alendronate and risedronate on serum lipid profile in postmenopausal women. Turkiye Fiziksel Tip ve Rehabilitasyon Dergisi. 2008;54:4-7.
10
175. Yen ML, Yen BL, Jang MH, Hsu SHJ, Cheng WC, Tsai KS. Effects of alendronate on osteopenic postmenopausal Chinese women. Bone. 2000;27(5):681-685.
176. Yeter A, Kavuncu V, Evcik FD, Demirdal US, Subasi V, Cakir T. Evalution the effects of raloxifene and risedronate on serum biochemical markers. Turk Osteoporoz Dergisi. 2014;20:110-116.
177. Yildirim K, Gureser G, Karatay S, et al. Comparison of the effects of alendronate, risedronate and calcitonin treatment in postmenopausal osteoporosis. J Back Musculoskelet Rehabil. 2005;18(3):85-89.
178. You L, Sheng ZY, Chen JY, Pan L, Chen L. The safety and efficacy of early-stage bi-weekly alendronate to improve bone mineral density and bone turnover in Chinese post-menopausal women at risk of osteoporosis. J Int Med Res. 2011;39(1):302-310.
179. Zebaze R, Libanati C, Austin M, Bilezikian J, Seeman E. Antiresorptive action is dependent on access to remodeling upon cortical and trabecular surfaces: Comparison of denosumab and alendronate. J Bone Miner Res. 2012.
180. Zebaze RM, Boyd SK, Nishiyama KK, et al. Denosumab decreases cortical porosity in postmenopausal women with low bone mineral density. Osteoporos Int. 2011:S527.
181. Zebaze RM, Libanati C, Austin M, Bilezikian JP, Seeman E. Denosumab reduces intracortical porosity more than alendronate in the compact-appearing cortex and outer transitional zone. Osteoporos Int. 2012:S291.
182. Zhang J, Zhang T, Xu X, Cai Q, Zhao D. Zoledronic acid combined with percutaneous kyphoplasty in the treatment of osteoporotic compression fracture in a single T12 or L1 vertebral body in postmenopausal women. Osteoporos Int. 2019;Apr 11:Epub ahead of print.
183. Zhang XZ, Song LG, Li H, et al. [Effects of alendronate on bone mineral density, cytokines and indices of bone metabolism in postmenopausal osteoporotic patients]. Zhonghua Nei Ke Za Zhi. 2006;45(7):565-568.
184. Zhang ZL, Liao EY, Xia WB, et al. Alendronate sodium/vitamin D3 combination tablet versus calcitriol for osteoporosis in Chinese postmenopausal women: a 6-month, randomized, open-label, active-comparator-controlled study with a 6-month extension. Osteoporos Int. 2015;26(9):2365-2374.
185. Zhou W, Liu Y, Guo X, Yang H, Xu Y, Geng D. Effects of zoledronic acid on bone mineral density around prostheses and bone metabolism markers after primary total hip arthroplasty in females with postmenopausal osteoporosis. Osteoporos Int. 2019;May 21.
186. Zhu HM, Tang H, Cheng Q, et al. Efficacy and safety of denosumab in Chinese postmenopausal women with osteoporosis at increased risk of fracture: Results from a 12-month, randomized, double-blind, placebo-controlled phase III study. J Bone Miner Res. 2017(Supplement 1):S160.
List of Included Studies (additional publications related to main trial publications)
1. Adachi JD, Adami S, Kulkarni PM, Wong M, Stock JL. Similar proportions of women lose bone mineral density with raloxifene or alendronate treatment. J Clin Densitom. 2005;8(3):273-277.
2. Adachi JD, McClung M, Minisola S, et al. Fracture incidence in postmenopausal women at higher risk of fracture after 3 years of denosumab treatment. Arthritis Rheum. 2009(60 Suppl 10):884.
3. Adachi JD, McClung MR, Cummings S, et al. Effect of denosumab on hip fractures in postmenopausal women: A subanalysis of the FREEDOM study. J Am Geriatr Soc. 2010;58(Suppl 1):S24.
4. Adami S, Baroni MC, Broggini M, et al. Treatment of postmenopausal osteoporosis with continuous daily oral alendronate in comparison with either placebo or intranasal salmon calcitonin. Osteoporos Int. 1993;3(Suppl 3):21-27.
5. Adami S, Gilchrist N, Lyritis G, et al. Effect of denosumab on fracture healing in postmenopausal women with osteoporosis: Results from the FREEDOM trial. Bone. 2010;47(Suppl 1):S63-S64.
6. Adami S, Libanati C, Adachi J, et al. Denosumab administration is not associated with fracture healing complications in postmenopausal women with osteoporosis: Results from the freedom trial. J Bone Miner Res. 2010;25(Suppl 1):S478-S479.
11
7. Adami S, Libanati C, Boonen S, et al. Denosumab treatment in postmenopausal women with osteoporosis does not interfere with fracture-healing: results from the FREEDOM trial. Journal of Bone and Joint SurgeryAmerican Volume. 2012;94(23):2113-2119.
8. Adami S, Palacios S, Pavelka K, et al. Freedom trial: Denosumab is not associated with fracture healing complications in postmenopausal women with osteoporosis. Osteoporos Int. 2011;22(Suppl 1):S243-S244.
9. Antoniucci DM, Sellmeyer DE, Bilezikian JP, et al. Elevations in serum and urinary calcium with parathyroid hormone (1-84) with and without alendronate for osteoporosis. J Clin Endocrinol Metab. 2007;92(3):942-947.
10. Antoniucci DM, Vittinghoff E, Palermo L, Black DM, Sellmeyer DE. Vitamin D insufficiency does not affect response of bone mineral density to alendronate. Osteoporos Int. 2009;20(7):1259-1266.
11. Bala Y, Chapurlat R, Felsenberg D, et al. Risedronate slows or partly reverses microarchitecture deterioration depending on whether remodelling is perturbed or in steady state. Osteoporos Int. 2013;1(Suppl 1):S58-S59.
12. Bauer DC, Black DM, Garnero P, et al. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res. 2004;19(8):1250-1258.
13. Bauer DC, Garnero P, Hochberg MC, et al. Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial. J Bone Miner Res. 2006;21(2):292-299.
14. Beck TJ, Michael LE, Miller PD, et al. Effects of Denosumab on the Geometry of the Proximal Femur in Postmenopausal Women in Comparison with Alendronate. J Clin Densitom. 2008;11(3):351-359.
15. Bettembuk P, Balogh A. The effect of a one-year alendronate therapy on postmenopausal osteoporosis. (Results in Hungarian of an international multicenter clinical study). Orv Hetil. 1999;140(50):2799–2803.
16. Black D, Delmas PD, Eastell R, et al. [Effect of an annual infusion with 5mg zoledronic acid in post-menopausal women with osteoporosis]. Med Klin. 2007;102(4):16.
17. Black D, Reid I, Cauley J, et al. The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: A randomized extension to the HORIZON-pivotal fracture trial (PFT). J Bone Miner Res. 2013(28):Conference.
18. Black DM, Bilezikian JP, Ensrud KE, et al. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. The New England Journal of Medicine. 2005;353(6):555-565.
19. Black DM, Eastell R, Cosman F, Man Z, Bucci-Rechtweg C, Mesenbrink P. Effect of once-yearly zoledronic acid 5 mg on a subset of six non-vertebral fractures. J Clin Densitom. 2010;13:132.
20. Black DM, Eastell R, Cosman F, et al. (Premier poster - Award candidate) Effect of once-yearly zoledronic acid 5 mg on 'Super Six' non-vertebral fractures. Osteoporos Int. 2009(20):S281.
21. Black DM, Reid IR, Boonen S, et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2012;27(2):243-254.
22. Black DM, Reid IR, Cauley JA, et al. The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: A randomized second extension to the HORIZON-pivotal fracture trial (PFT). J Bone Miner Res. 2015;30(5):934-944.
23. Black DM, Reiss TF, Nevitt MC, Cauley J, Karpf D, Cummings SR. Design of the Fracture Intervention Trial. Osteoporos Int. 1993;3(Suppl 3):29-39.
24. Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. The Journal of clinical endocrinology and metabolism. 2000;85(11):4118-4124.
25. Blake GM, Herd RJM, Patel R, Fogelman I. The effect of weight change on total body dual-energy X-ray absorptiometry: Results from a clinical trial. Osteoporos Int. 2000;11(10):832-839.
26. Boivin GY, Chavassieux PM, Santora AC, Yates J, Meunier PJ. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone. 2000;27(5):687-694.
12
27. Bolland M, Wattie D, Horne A, Gamble G, Reid IR, Grey A. Prolonged anti-resorptive activity of zoledronate-A randomized controlled trial. Bone. 2010;47:S56-S57.
28. Bolognese MA, Bone HG, Kendler DL, et al. Transitioning to denosumab leads to further increases in BMD throughout the skeleton in postmenopausal women who received 5 or more years of continuous alendronate therapy. Arthritis Rheum. 2011;63( Suppl 1).
29. Bolognese MA, Roux C, Bianchi G, et al. Relationship of baseline bone turnover marker levels and month 12 bone mineral density change in postmenopausal women transitioned from alendronate to denosumab. Arthritis Rheum. 2009(60 Suppl 10):871.
30. Bolognese MA, Teglbjaerg CS, Zanchetta JR, et al. Denosumab significantly increases DXA BMD at both trabecular and cortical sites: results from the FREEDOM study. J Clin Densitom. 2013;16(2):147-153.
31. Bone H, Brandi ML, Brown J, et al. Ten years of denosumab treatment in postmenopausal women with osteoporosis: Results from the freedom extension trial. J Rheumatol. 2016(6):1209.
32. Bone HG, Chapurlat R, Franchimont N, et al. Six years of denosumab treatment in postmenopausal women with osteoporosis: Results from the first three years of the freedom. Arthritis Rheum. 2011;63(12):4044-4045.
33. Bone HG, Hosking D, Devogelaer JP, et al. Ten Years' Experience with Alendronate for Osteoporosis in Postmenopausal Women. N Engl J Med. 2004;350(12):1189-1199.
34. Bone HG, Kendler DL, Bolognese MA, et al. Transitioning to denosumab further improves BMD in postmenopausal women who received 5 or more years of continuous alendronate therapy. Endocr Rev. 2011;3:Meeting Abstracts.
35. Bone HG, Wagman RB, Brandi ML, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017;5(7):513-523.
36. Bonnick S, Rosen C, Mako B, Delucca P, Byrned C, Melton M. Alendronate vs calcium for treatment of osteoporosis in postmenopausal women. Bone. 1998;350:S476.
37. Bonnick S, Saag KG, Kiel DP, et al. Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. J Clin Endocrinol Metab. 2006;91(7):2631-2637.
38. Boonen S, Adachi JD, Man Z, et al. Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. J Clin Endocrinol Metab. 2011;96(6):1727-1736.
39. Boonen S, Lippuner K, Adachi JD, et al. Denosumab reduced the incidence of hip and new vertebral fractures in postmenopausal women with higher fracture risk: A subanalysis of the FREEDOM study. Osteoporos Int. 2010;21(Suppl 5):S746-S747.
40. Boonen S, McClung M, Minisola S, et al. Antifracture effects of denosumab in postmenopausal women at higher fracture risk: A subgroup analysis from the freedom trial. Osteoporos Int. 2010;22(Suppl 1):S376-S377.
41. Boonen S, Sellmeyer DE, Lippuner K, et al. Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney Int. 2008;74(5):641-648.
42. Borah B, Dufresne T, Nurre J, et al. Risedronate reduces intracortical porosity in postmenopausal women with osteoporosis as measured by a new 3D Micro-CT method. Bone. 2010;46:S61.
43. Borah B, Dufresne T, Nurre J, et al. Risedronate reduces intracortical porosity in women with osteoporosis. J Bone Miner Res. 2010;25(1):41-47.
44. Borah B, Dufresne TE, Chmielewski PA, Johnson TD, Chines A, Manhart MD. Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography. Bone. 2004;34(4):736-746.
45. Borah B, Ritman EL, Dufresne TE, et al. The effect of risedronate on bone mineralization as measured by micro-computed tomography with synchrotron radiation: correlation to histomorphometric indices of turnover. Bone. 2005;37(1):01-Sep.
46. Boskey AL, Bauer DC, Ensrad K, Black DM, Schwartz AV. Insights into the bisphosphonate-holiday: a preliminary FTIRI study. J Orthop Res. 2016:34.
47. Bouxsein ML, Parker RA, Greenspan SL. Forearm bone mineral densitometry cannot be used to monitor response to alendronate therapy in postmenopausal women. Osteoporos Int. 1999;10(6):505-509.
13
48. Brown JP, Bone HG, Chapurlat R, et al. Extended safety observations from denosumab administration in postmenopausal women from the freedom and freedom extension trials. Arthritis Rheum. 2011;63( Suppl 1).
49. Brown JP, Deal C, De Gregorio LH, et al. Effect of Denosumab vs alendronate on bone turnover markers and bone mineral density changes at 12 months based on baseline bone turnover level. J Rheumatol. 2009;36(11):2590-2591.
50. Brown JP, Yue S, Farlay D, et al. Effects of denosumab on bone matrix mineralization: Results from the phase 3 FREEDOM trial. J Bone Miner Res. 2015(Suppl 1).
51. Cauley JA, Black D, Boonen S, et al. Once-yearly zoledronic acid and days of disability, bed rest, and back pain: randomized, controlled HORIZON Pivotal Fracture Trial. J Bone Miner Res. 2011;26(5):984-992.
52. Chapurlat R, Portero-Muzy N, Roux JP, et al. Denosumab reduced bone remodeling, eroded surface, and erosion depth in cortical bone of iliac crest biopsies from postmenopausal women in the FREEDOM Trial. J Bone Miner Res. 2017(Suppl 1):S38.
53. Chapurlat RD, Palermo L, Ramsay P, Cummings SR. Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention Trial. Osteoporos Int. 2005;16(7):842-848.
54. Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest. 1997;100(6):1475-1480.
55. Chrischilles EA, Dasbach EJ, Rubenstein LM, et al. The effect of alendronate on fracture-related healthcare utilization and costs: the fracture intervention trial. Osteoporos Int. 2001;12(8):654-660.
56. Cosman F, Cauley JA, Eastell R, et al. Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment? J Clin Endocrinol Metab. 2014;99(12):4546-4554.
57. Cosman F, Eriksen EF, Recknor C, et al. Effects of once-yearly zoledronic acid 5 mg in combination with teriparatide (PTH) on postmenopausal women with osteoporosis. Bone. 2010;47:S55-S56.
58. Cosman F, Gilchrist N, McClung M, et al. A phase IIb study of MK-5442 calcium sensing receptor (CASR) antagonist in bisphosphonate-treated patients. J Bone Miner Res. 2012(27):Conference.
59. Cummings S, Wang A, Martin JS, et al. The effect of denosumab on bone turnover markers (BTM) in postmenopausal women with osteoporosis. Bone. 2010(Suppl 1):S28.
60. Cummings SR, Palermo L, Browner W, et al. Monitoring osteoporosis therapy with bone densitometry: Misleading changes and regression to the mean. JAMA. 2000;283(10):1318-1321.
61. Devogelaer JP, Broll H, Correa-Rotter R, et al. Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis. Bone. 1996;18(2):141-150.
62. Downs RW, Bone HG, McIlwain H, et al. An open-label extension study of alendronate treatment in elderly women with osteoporosis. Calcif Tissue Int. 1999;64(6):463-469.
63. Dufresne TE, Chmielewski PA, Manhart MD, Johnson TD, Borah B. Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomography. Calcif Tissue Int. 2003;73(5):423-432.
64. Duque G, Li W, Adams M, Xu S, Phipps R. Effects of risedronate on bone marrow adipocytes in postmenopausal women. Osteoporos Int. 2011;22(5):1547-1553.
65. Durchschlag E, Paschalis EP, Zoehrer R, et al. Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate. J Bone Miner Res. 2006;21(10):1581-1590.
66. E CRS. Risedronate reduces cortical structural decay during menopause, probably by reducing intracortical porosity. Osteoporos Int. 2011;22(Suppl 1):S100.
67. Eastell R, Austin M, San MJ, et al. Effect of denosumab on bone turnover markers in postmenopausal osteoporosis: Initial response and subsequent release from suppression. Bone. 2009(Suppl 2):S242-S243.
14
68. Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res. 2003;18(6):1051-1056.
69. Eastell R, Black DM, Boonen S, et al. Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density. J Clin Endocrinol Metab. 2009;94(9):3215-3225.
70. Eastell R, Black DM, Boonen S, et al. Once-Yearly zoledronic acid 5 mg infusion for treatment of postmenopausal osteoporosis: Effects on fracture incidence in patient subgroups from the HORIZON-PFT study. Rheumatology. 2009(48):i105.
71. Eastell R, Christiansen C, Grauer A, et al. Relationship between reduction in bone turnover markers (BTM) and change in bone mineral density (BMD) in women with postmenopausal osteoporosis treated with denosumab. Osteoporos Int. 2010;22(Suppl 1):S185-S186.
72. Eastell R, Lang T, Boonen S, et al. Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial. Osteoporos Int. 2010;21(7):1277-1285.
73. Eastell R, Nagase S, Boonen S, et al. Efficacy and safety of the cathepsin K inhibitor, ONO-5334, in the treatment of postmenopausal osteopenia or osteoporosis. Bone. 2010(47):S50.
74. Eastell R, Nagase S, Small M, et al. Effect of the cathepsin k inhibitor, ONO-5334, on biochemical markers of bone turnover in the treatment of postmenopausal osteopenia or osteoporosis: 2-year results from the ocean study. J Bone Miner Res. 2011(26).
75. Eastell R, Nagase S, Small M, et al. Effect of ONO-5334 on bone mineral density and biochemical markers of bone turnover in postmenopausal osteoporosis: 2-year results from the OCEAN study. J Bone Miner Res. 2014;29(2):458-466.
76. Eastell R, Nagase S, Small M, et al. Effect of the cathepsin K inhibitor, ONO-5334, on biochemical markers of bone turnover in the treatment of postmenopausal osteopenia or osteoporosis. J Bone Miner Res. 2010;25:S21.
77. Eastell R, Paggiosi M, Peel N, McCloskey E, Walsh J. The effects of oral bisphosphonate therapy on the peripheral skeleton in postmenopausal osteoporosis: The TRIO study. J Bone Miner Res. 2013(28):Conference.
78. Eastell R, Palermo L, Bauer D, Cummings S, Black DM, Bucci-Rechtweg C. What accounts for an inadequate response to zoledronic acid? Bone. 2010;47:S200.
79. Engelke K, Nagase S, Fuerst T, et al. Effects of the cathepsin K inhibitor, ONO-5334, on BMD as measured by 3D QCT in the hip and the spine after 12 months treatment. J Bone Miner Res. 2010;25:S127.
80. Engelke K, Nagase S, Fuerst T, et al. Effects of the cathepsin k inhibitor, ONO-5334, on BMD as measured by 3d QCT in the hip and the spine after 2years of treatment. J Bone Miner Res. 2011(26).
81. Engelke K, Nagase S, Fuerst T, et al. The effect of the cathepsin K inhibitor ONO-5334 on trabecular and cortical bone in postmenopausal osteoporosis: the OCEAN study. J Bone Miner Res. 2014;29(3):629-638.
82. Ensrud KE, Barrett-Connor EL, Schwartz A, et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: Results from the fracture intervention trial long-term extension. J Bone Miner Res. 2004;19(8):1259-1269.
83. Ensrud KE, Black DM, Palermo L, et al. Treatment with alendronate prevents fractures in women at highest risk: Results from the fracture intervention trial. Arch Intern Med. 1997;157(22):2617-2624.
84. Eriksen EF, Melsen F, Sod E, Barton I, Chines A. Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. Bone. 2002;31(5):620-625.
85. F. G, Hoyle C, Naylor KE, et al. The effect of bisphosphonates on bone turnover and bonebalance in postmenopausal women with osteoporosis: The T-score bonemarker approach in the TRIO study. Osteoporos Int. 2018(Suppl 2):S621-S622.
86. Felicia C, Saag K, Eriksen E, et al. Effects of once-yearly zoledronic acid 5mg in combination with Teriparatide (PTH) on postmenopausal women with osteoporosis. Arthritis Rheum. 2009;60:S591.
15
87. Felsenberg D, Alenfeld F, Bock O, Hammermeister C, Gowan W. Placebo-controlled multicenter study of oral alendronate in postmenopausal osteoporotic women. Maturitas. 1998;31(1):35-44.
88. Ferrari S, Adachi JD, Lippuner K, et al. Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years. Osteoporos Int. 2015;26(12):2763-2771.
89. Ferrari S, Butler P, Kendler DL, et al. Ten-year continued nonvertebral fracture reduction in postmenopausal osteoporosis with denosumab treatment. J Bone Miner Res. 2017(Suppl 1):S25.
90. Fink HA, Ensrud KE, Nelson DB, et al. Disability after clinical fracture in postmenopausal women with low bone density: The fracture intervention trial (FIT). Osteoporos Int. 2003;14(1):69-76.
91. Freemantle N, Kendler D, Kaur P, et al. DAPS (denosumab adherence preference satisfaction): Results of the second year of the crossover study. Osteoporos Int. 2011(22):S98.
92. Freemantle N, Satram-Hoang S, Tang ET, et al. Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int. 2011:1-10.
93. Gamsjaeger S, Buchinger B, Zwettler E, et al. Bone material properties in actively bone-forming trabeculae in postmenopausal women with osteoporosis after three years of treatment with once-yearly Zoledronic acid. J Bone Miner Res. 2011;26(1):Dec-18.
94. Gamsjaeger S, Hofstetter B, Zwettler E, et al. Effects of 3 years treatment with once-yearly zoledronic acid on the kinetics of bone matrix maturation in osteoporotic patients. Osteoporos Int. 2013;24(1):339-347.
95. Genant H, Engelke K, Zanchetta JR, et al. Hip QCT results from the freedom trial: Evidence for positive BMD/BMC changes in integral, trabecular, and cortical bone with denosumab. J Bone Miner Res. 2010;25(Suppl 1):S127.
96. Genant H, Radcliffe H, Libanati C, et al. BMD and BMC improvements in hip total, trabecular, and cortical bone following denosumab treatment: QCT results from the freedom trial. Osteoporos Int. 2011;22(Suppl 1):S116-S117.
97. Genant HK, Bucci-Rechtweg C, Bauer DC, et al. Does zoledronic acid increase risk of atypical femoral shaft fractures? results from the HORIZON-PFT. Osteoporos Int. 2010(21):S161-S162.
98. Genant HK, Engelke K, Hanley DA, et al. Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density. Bone. 2010;47(1):131-139.
99. Genant HK, Engelke K, Zanchetta JR, et al. Denosumab treatment results in significant trabecular and cortical bone improvements at the hip as assessed by QCT. Bone. 2011;48(Suppl 2):S88-S89.
100. Genant HK, Keaveny TM, Zapalowski C, et al. Cortical bone parameters at the hip in response to denosumab vs placebo and the clinical relevance of these changes in postmenopausal women with osteoporosis <75 and >=75 years old. J Bone Miner Res. 2013;28(Suppl 1).
101. Genant HK, Zanchetta JR, Kendler D, et al. Denosumab increases total, trabecular, and cortical estimated hip and spine strength in postmenopausal women with osteoporosis. Bone. 2011;48( Suppl 2):S86-S87.
102. Goemaere S, Zmierczak H, Batens AH, et al. Can zoledronic acid treatment improve bone strength parameters assessed by pQCT: A pilot study. Osteoporos Int. 2010(21):S57-S58.
103. Gossiel F, Hoyle C, McCloskey EV, et al. The effect of bisphosphonate treatment on osteoclast precursor cells in postmenopausal osteoporosis: The TRIO study. Bone. 2016;92:94-99.
104. Greenspan SL, Beck TJ, Resnick NM, Bhattacharya R, Parker RA. Effect of hormone replacement, alendronate, or combination therapy on hip structural geometry: A 3-year, double-blind, placebo-controlled clinical trial. J Bone Miner Res. 2005;20(9):1525-1532.
105. Greenspan SL, Emkey RD, Bone III HG, et al. Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis: A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2002;137(11):875-883.
106. Grey A, Bolland M, Mihov B, et al. Duration of antiresorptive effects of low-dose zoledronate in osteopenic postmenopausal women: a randomized, placebo-controlled trial. J Bone Miner Res. 2014;29(1):166-172.
16
107. Grey A, Bolland M, Wong S, Horne A, Gamble G, Reid IR. A randomized controlled trial of annual low-dose zoledronate in postmenopausal women. Endocr Rev. 2011;32:Meeting Abstracts.
108. Grey A, Bolland MJ, Horne A, Mihov B, Gamble G, Reid IR. Duration of antiresorptive activity of zoledronate in postmenopausal women with osteopenia: a randomized, controlled multidose trial. Can Med Assoc J. 2017;189(36):E1130-E1136.
109. Grey A, Bolland MJ, Wattie D, Horne A, Gamble G, Reid IR. The antiresorptive effects of a single dose of zoledronate persist for two years: A randomized, placebo-controlled trial in osteopenic postmenopausal women. J Clin Endocrinol Metab. 2009;94(2):538-544.
110. Hadji P, Gamerdinger D, Spieler W, et al. Rapid onset and sustained efficacy (ROSE) study of zoledronic acid vs alendronate in postmenopausal women with osteoporosis: Quality of life (QOL), compliance and therapy preference. J Bone Miner Res. 2010;25:S336.
111. Hadji P, Gamerdinger D, Spieler W, et al. (Premier Poster-Award Candidate) Zoledronic acid vs. alendronate: first results from the rapid onset and sustained efficacy (ROSE) study. Osteoporos Int. 2010(21):S465-S466.
112. Hadji P, Gamerdinger D, Spieler W, et al. Rapid Onset and Sustained Efficacy (ROSE) study: results of a randomised, multicentre trial comparing the effect of zoledronic acid or alendronate on bone metabolism in postmenopausal women with low bone mass. Osteoporos Int. 2011:1-9.
113. Hadji P, Ziller V, Gamerdinger D, et al. Quality of life and health status with zoledronic acid and generic alendronate--a secondary analysis of the Rapid Onset and Sustained Efficacy (ROSE) study in postmenopausal women with low bone mass. Osteoporos Int. 2012;23(7):2043-2051.
114. Hadji P, Ziller V, Gamerdinger D, Spieler W, Moricke R, Kann PH. Summary of the results of the ROSE-Study: Direct comparison of the two bisphosphonates alendronate and zoledronic acid. Osteologie. 2012;21(2):94-100.
115. Hadji P, Ziller V, Loffler H, Kolter T, Articus K. [Comparison of speed to take effect and the long-lasting effect of 5 mg zoledronic acid i.v. and 70mg alendronate p.o. in the treatment of patients with post-menopausal osteoporosis]. Med Klin. 2008;103(3):17, 2008.
116. Harris ST, Watts NB, Li Z, Chines AA, Hanley DA, Brown JP. Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis. Curr Med Res Opin. 2004;20(5):757-764.
117. Herd RM, Blake GM, Ryan PJ, Fogelman I. A 152 patient double blind placebo controlled study of cyclical etidronate therapy for the prevention of early postmenopansal bone loss. J Bone Miner Res. 1995;10(Suppl 1):S153.
118. Hochberg MC, Ross PD, Black D, et al. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group. Arthritis Rheum. 1999;42(6):1246-1254.
119. Hofbauer LC, Fahrleitnerpammer A, Ho PR, et al. Efficacy and safety of denosumab vs. Risedronate in postmenopausal women suboptimally adherent to alendronate: Results from a randomized open-label study. Osteoporos Int. 2013;24(Suppl 1):S218-S219.
120. Hooper M, Ebeling P, Roberts A. Risedronate prevents bone loss in early postmenopausal women. Calcif Tissue Int. 1999(Suppl 1):80.
121. Hosking D, Adami S, Felsenberg D, et al. Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: A randomised, placebo-controlled study. Curr Med Res Opin. 2003;19(5):383-394.
122. Hwang JS, Chin LS, Chen JF, et al. The effects of intravenous zoledronic acid in Chinese women with postmenopausal osteoporosis. J Bone Miner Metab. 2011;29(3):328-333.
123. Jacques RM, Boonen S, Cosman F, et al. Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2012;27(8):1627-1634.
124. Jamal S, Ljunggren O, Stehman-Breen C, et al. The effects of denosumab on bone mineral density (BMD) and fracture by level of renal function. Bone. 2010;47(Suppl 1):S207-S208.
125. Jamal SA, Bauer DC, Ensrud KE, et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. J Bone Miner Res. 2007;22(4):503-508.
17
126. Jamal SA, Ebeling PR, Ljunggren O, et al. The effects of denosumab (DMAb) on bone mineral density (BMD), fracture and safety outcomes by level of renal function. Arthritis Rheum. 2010(62 Suppl 10):982.
127. Jamal SA, Ljunggren O, Stehman-Breen C, et al. The effects of denosumab on bone mineral density (BMD) and fracture by level of renal function. J Bone Miner Res. 2010;25(Suppl 1):S21-S22.
128. Kanis JA, Barton IP, Johnell O. Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture. Osteoporos Int. 2005;16(5):475-482.
129. Keaveny T, McClung M, Genant H, et al. Denosumab improves both femoral and vertebral strength in women with osteoporosis: Results from the FREEDOM trial. J Bone Miner Res. 2010;25(Suppl 1):S31.
130. Keaveny TM, McClung MR, Genant HK, et al. Femoral and vertebral strength improvements in postmenopausal women with osteoporosis treated with denosumab. J Bone Miner Res. 2014;29(1):158-165.
131. Keegan TH, Schwartz AV, Bauer DC, Sellmeyer DE, Kelsey JL. Effect of alendronate on bone mineral density and biochemical markers of bone turnover in type 2 diabetic women: The fracture intervention trial. Diabetes Care. 2004;27(7):1547-1553.
132. Kendler D, Lillestol MJ, Moffett AH, et al. Influence of patient perceptions and preferences about osteoporosis medication on adherence in the denosumab adherence, preference, and satisfaction (DAPS) study. Menopause. 2012;19(12):1390.
133. Kendler DL, Brandi ML, Papapoulos S, et al. The risk of subsequent osteoporotic fractures is decreased in patients experiencing fracture while on denosumab: results from the freedom and freedom extension studies. J Bone Miner Res. 2017;31.
134. Kendler DL, Chines A, Brandi ML, et al. The risk of subsequent osteoporotic fractures is decreased in subjects experiencing fracture while on denosumab: results from the FREEDOM and FREEDOM Extension studies. Osteoporos Int. 2019;30(1):71-78.
135. Kendler DL, Chines A, Brandi ML, et al. The risk of subsequent osteoporotic fractures is decreased in patients experiencing fracture while on denosumab. Arthritis and Rheumatology. 2016(Suppl 10):428-430.
136. Kendler DL, Macarios D, Lillestol MJ, et al. Influence of patient perceptions and preferences for osteoporosis medication on adherence behavior in the Denosumab Adherence Preference Satisfaction study. Menopause. 2014;21(1):25-32.
137. Kendler DL, McClung MR, Freemantle N, et al. Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate. Osteoporos Int. 2011;22(6):1725-1735.
138. Kendler DL, Roux C, Benhamou CL, et al. Effects of denosumab in postmenopausal women transitioning from alendronate therapy in comparison with continued alendronate. J Rheumatol. 2009;36(11):2566-2567.
139. Kiel DP, Siddhanti S, Daizadeh N, Wang A, Anthony M, Christiansen C. Effect of denosumab on 3-year progression of aortic calcification in postmenopausal women with osteoporosis at high risk for cardiovascular events. Bone. 2010;47(Suppl 1):S69.
140. Kushida K, Shiraki M, Nakamura T, et al. Alendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis: A 3-year follow-up study. J Bone Miner Metab. 2004;22(5):462-468.
141. Langdahl B, Benhamou CL, Johnston CC, et al. Resolution of effects on bone turnover markers and bone mineral density after discontinuation of long-term bisphosphonate use. J Bone Miner Res. 2012(27).
142. Libanati C, Boyd SK, Nishiyama KK, et al. Denosumab decreases cortical porosity in postmenopausal women with low bone mineral density. Arthritis Rheum. 2011;63(Suppl 1).
143. Libanati C, Thomas T, Boyd S, et al. Denosumab and alendronate have different effects at the ultradistal radius in postmenopausalwomen with low bone mass. Bone. 2010;46(Suppl 1):S28-S29.
144. Masud T, McClung M, Geusens P. Reducing hip fracture risk with risedronate in elderly women with established osteoporosis. Clin Interv Aging. 2009;4:445-449.
18
145. McClung M, Bauer D, Christiansen C, et al. The effects of denosumab on fracture risk reduction related to baseline bone resorption. Arthritis Rheum. 2009(60 Suppl 10):593.
146. McClung M, Bensen W. Risedronate treatment of postmenopausal women with low bone mass: preliminary data. Osteoporos-Int. 1996;Suppl 1:257.
147. McClung M, Bensen WG, Bolognese M, Bonnick S, Ettinger M, Harris ST. Risedronate increases bone mineral density at the hip, spine and radius in postmenopausal women with low bone mass. Osteoporos Int. 1998;8(Suppl 3):111.
148. McClung M, Bolognese M, Miller P, et al. Bmd response to a novel delayed-release risedronate 35 mg once-a-week formulation taken with or without breakfast: One year results. J Bone Miner Res. 2010(25):S124.
149. McClung M, Grauer A, Boonen S, et al. Inhibition of sclerostin with romosozumab in postmenopausalwomen with low BMD: Phase 2 trial results. Osteoporos Int. 2013;24(Suppl 2):S38-S39.
150. McClung M, Lewiecki EM, Bolognese MA, et al. Effects of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial. J Bone Miner Res. 2011(26).
151. McClung MR, Balske A, Burgio DE, Wenderoth D, Recker RR. Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years. Osteoporos Int. 2013;24(1):301-310.
152. McClung MR, Benhamou CL, Man Z, et al. A novel monthly dosing regimen of risedronate for the treatment of postmenopausal osteoporosis: 2-year data. Calcif Tissue Int. 2013;92(1):59-67.
153. McClung MR, Bolognese MA, Miller PD, Brown JP, Recker RR. BMD response to delayed-release risedronate 35 mg once-a-week formulation taken with or without breakfast. J Clin Densitom. 2010;13:S132.
154. McClung MR, Boonen S, Torring O, et al. Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis. J Bone Miner Res. 2012;27(1):211-218.
155. McClung MR, Chines A, Brown JP, et al. Effects of 2 years of treatment with romosozumab followed by 1 year of denosumab or placebo in postmenopausal women with low bone mineral density. Ann Rheum Dis. 2015;74(Suppl 2):166-167.
156. McClung MR, Chines A, Brown JP, et al. Results of 2 years of romosozumab treatment followed by 1 year of denosumab or placebo in postmenopausal women with low bone mineral density. Osteoporos Int. 2015;26(Suppl 1):S36-S37.
157. McClung MR, Freemantle N, Kendler DL, et al. Open-label study to evaluate the adherence, preference, and satisfaction of denosumab and alendronate in postmenopausal women. Osteoporos Int. 2010(21):S386.
158. McClung MR, Lewiecki EM, Geller ML, et al. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial. Osteoporos Int. 2013;24(1):227-235.
159. McClung MR, Lippuner K, Brandi ML, et al. In postmenopausal women with osteoporosis, denosumab significantly improved trabecular bone score (TBS), an index of trabecular microarchitecture. Arthritis Rheum. 2012;64(Suppl 10):S832.
160. McClung MR, Michael LE, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006;354(8):821-831.
161. McClung MR, Wasnich RD, Hosking DJ, et al. Prevention of postmenopausal bone loss: Six-year results from the early postmenopausal intervention cohort study. J Clin Endocrinol Metab. 2004;89(10):4879-4885.
162. McClung MR, Zanchetta JR, Benhamou CL, Balske A, Sarley J, Recker RR. Effect of a delayed-release risedronate 35 mg once-a-week formulation taken with or without breakfast on BMD. Osteoporos Int. 2010(21):S25.
163. McClung MR, Zanchetta JR, Racewicz A, et al. Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data. Osteoporos Int. 2013;24(1):293-299.
19
164. Mellstrom DD, Sorensen OH, Goemaere S, Roux C, Johnson TD, Chines AA. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int. 2004;75(6):462-468.
165. Meunier PJ, Confavrenx E, Tupinon I, Hardouin C, Lockwood C, Balena R. Cyclical etidronate therapy prevents bone loss in the early postmenopausal period. J Bone Miner Res. 1995;10(Suppl 1):S357.
166. Miller P, Pannacciulli N, Brown JP, et al. A randomized double-blind study of denosumab (DMAB) compared with zoledronic acid (ZOL) in postmenopausal women with osteoporosis previously treated with oral bisphosphonates. Osteoporos Int. 2016;27(Suppl 1):S41.
167. Miller P, Roux C, McClung M, Adami S, Eastell R, Ethgen D. Risedronate reduces hip fractures in patients with low femoral neck bone mineral density Arthritis Rheum. 1999;42:S287.
168. Miller PD, Black DM, Hruska J, Boonen S. Renal effects of treatment with zoledronic acid: Results from the horizon-PFT extension study. Osteoporos Int. 2012;23:S197-S198.
169. Miller PD, Bolognese MA, Lewiecki EM, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone. 2008;43(2):222-229.
170. Miller PD, Watts NB, Licata AA, et al. Cyclical etidronate in the treatment of postmenopausal osteoporosis: Efficacy and safety after seven years of treatment. Am J Med. 1997;103(6):468-476.
171. Munoz-Torres M, Roig-Escofet D, Lozano C, et al. Efficacy of alendronate in treatment of a Spanish population of postmenopausal women with low bone mass. Spanish results in the international fosit trial. Revista Espanola de Enfermedades Metabolicas Oseas. 2004;13(6):122-128.
172. N.B. Watts CR, H. Genant, S. Adami, T. Hangartner, P. Miller. Risedronate reduces vertebral fracture risk after the first year of treatment in postmenopausal women with established osteoporosis. J Bone Miner Res. 1999;14(Suppl 1):S136.
173. Nakamura T, Matsumoto T, Sugimoto T, Shiraki M. Evaluation of efficacy and safety of denosumab in Japanese postmenopausal women with osteoporosis-phase II (dose response) study. Osteoporos Int. 2012;23(Suppl 2):S133-S134.
174. Nevitt MC, Ross PD, Palermo L, Musliner T, Genant HK, Thompson DE. Association of prevalent vertebral fractures, bone density, and alendronate treatment with incident vertebral fractures: effect of number and spinal location of fractures. The Fracture Intervention Trial Research Group. Bone. 1999;25(5):613-619.
175. Nevitt MC, Silverman SL, Viswanathan H, et al. Impact of incident clinical vertebral fractures on back pain outcomes in postmenopausal women who participated in the FREEDOM trial. Arthritis Rheum. 2010(62 Suppl 10):971.
176. Nevitt MC, Thompson DE, Black DM, et al. Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures. Fracture Intervention Trial Research Group. Arch Intern Med. 2000;160(1):77-85.
177. Paggiosi MA, Walsh JS, Peel NFA, McCloskey EV, Eastell R. A comparison of the effects of three oral bisphosphonates on the peripheral skeleton in postmenopausal osteoporosis: The trio study. Osteoporos Int. 2014;25( Suppl 1):S692.
178. Palacios S, Kalouche-Khalil L, Rizzoli R, et al. Treatment with denosumab reduces secondary fracture risk in women with postmenopausal osteoporosis. Climacteric. 2015;18(6):805-812.
179. Palacios S, Rizzoli R, Zapalowski C, et al. Denosumab reduced osteoporotic fractures in postmenopausal women with osteoporosis with prior fracture: Results from freedom. Osteoporos Int. 2013;24(Suppl 1):S299-S300.
180. Pannacciulli N, Czerwinski E, Nedergaard BS, et al. Denosumab compared with zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates: Efficacy and safety results from a randomized double-blind study. J Bone Miner Res. 2015(Suppl 1).
181. Papapoulos S, Chapurlat R, Libanati C, et al. Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res. 2012;27(3):694-701.
20
182. Papapoulos S, Lewiecki EM, Dakin P, et al. Safety observations with three years of denosumab exposure: Comparison between subjects who received denosumab during FREEDOM and subjects who crossed over to denosumab during the FREEDOM Extension. J Bone Miner Res. 2015(Suppl 1).
183. Papapoulos S, Lippuner K, Roux C, et al. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study. Osteoporos Int. 2015;26(12):2773-2783.
184. Papapoulos S, Roux C, Bone HG, et al. Denosumab treatment in postmenopausal women with osteoporosis for up to 9 years: Results through year 6 of the freedom extension. Ann Rheum Dis. 2015;74(Suppl 2):529-530.
185. Poole K, Treece G, Gee A, et al. Progressive improvements in cortical mass and thickness throughout the hip were observed with denosumab treatment in the freedom Trial. Arthritis Rheum. 2012;64(Suppl 10):S358-S359.
186. Poole K, Treece GM, Gee A, et al. Denosumab treatment is associated with progressive improvements in cortical mass and thickness throughout the hip. J Bone Miner Res. 2012;27(Suppl 1).
187. Popp A, Buffat H, Lamy O, Perrelet R, Hans D, Lippuner K. Beneficial effects of zoledronate versus placebo on lumbar spine bone mineral density (BMD) and microstructural parameters (TBS) in postmenopausal women with osteoporosis. A 3-year study. J Bone Miner Res. 2012(27).
188. Popp A, Buffat H, Senn C, Okere I, Perrelet R, Lippuner K. Zoledronate prevents tibial bone loss in postmenopausal women with osteoporosis. J Bone Miner Res. 2010;25:S208.
189. Popp AW, Buffat H, Cavelti A, et al. Cortical bone loss at the tibia in postmenopausal women with osteoporosis is associated with incident non-vertebral fractures: results of a randomized controlled ancillary study of HORIZON. Maturitas. 2014;77(3):287-293.
190. Popp AW, Guler S, Lamy O, et al. Effects of zoledronate versus placebo on spine bone mineral density and microarchitecture assessed by the trabecular bone score in postmenopausal women with osteoporosis: a three-year study. J Bone Miner Res. 2013;28(3):449-454.
191. Pouilles JM, Tremollieres F. Early intervention: new clinical results. Cyclical etidronate for the prevention of early postmenopausal bone loss. Osteoporos Int. 1996;Suppl 1:242.
192. Quandt SA, Thompson DE, Schneider DL, Nevitt MC, Black DM, Fracture Intervention Trial Research Group. Effect of alendronate on vertebral fracture risk in women with bone mineral density T scores of-1.6 to -2.5 at the femoral neck: the Fracture Intervention Trial. Mayo Clin Proc. 2005;80(3):343-349.
193. Ravn P, Clemmesen B, Christiansen C. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Bone. 1999;24(3):237-244.
194. Ravn P, Hosking D, Thompson D, et al. Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. J Clin Endocrinol Metab. 1999;84(7):2363-2368.
195. Reginster JY, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int. 2000;11(1):83-91.
196. Reid DM, Hosking D, Kendler D, et al. Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis: Results of FACTS 1 -International. Clin Drug Investig. 2006;26(2):63-74.
197. Reid I, Horne A, Mihov B, et al. Zoledronate every 18 months for 6 years in osteopenic postmenopausal women: Effects on fractures and non-skeletal endpoints. JBMR Plus. 2018(Suppl 1):S14.
198. Reid I, Horne A, Mihov B, et al. Zoledronate every 18 months for 6 years in osteopenic postmenopausal women reduces non-vertebral fractures and height loss. Calcif Tissue Int. 2018;1(Suppl 1):S22-S23.
199. Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med. 2002;346(9):653-661.
200. Reid IR, Gamble GD, Mesenbrink P, Black DM. Characterization of and risk factors for acute phase reactions following Zoledronic acid. Osteoporos Int. 2010(21):S356-S357.
21
201. Reid IR, Gamble GD, Mesenbrink P, Lakatos P, Black DM. Characterization of and risk factors for the acute-phase response after zoledronic acid. J Clin Endocrinol Metab. 2010;95(9):4380-4387.
202. Reid IR, Horne AM, Mihov B, et al. Anti-fracture efficacy of zoledronate in subgroups of osteopenic postmenopausal women: secondary analysis of a randomized controlled trial. J Intern Med. 2019;March 18.
203. Ribot R, Smith I, Fogelman S, Pack D. Risedronate increases bone mineral density and is well tolerated in postmenopausal women with low bone mineral density. J Bone Miner Res. 1999;14:S163.
204. Rizzoli R, Boonen S, Bone HG, et al. The effect of denosumab on vertebral fracture risk by type and subgroup: Results from the FREEDOM trial. Osteoporos Int. 2010;22(Suppl 1):S357-S358.
205. Rizzoli R, Greenspan SL, Bone G, et al. Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res. 2002;17(11):1988-1996.
206. Rolland Y, de Souto Baretto P, Cesari M, et al. Denosumab (DMAB) and total lean body mass: Exploratory analyses from the freedom study. J Bone Miner Res. 2017(Suppl 1).
207. Rosen CJ, Hochberg MC, Bonnick SL, et al. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res. 2005;20(1):141-151.
208. Roux C, Fahrleitner-Pammer A, Ho PR, et al. Denosumab compared with risedronate in postmenopausal women suboptimally adherent with alendronate therapy: Efficacy and safety results from a randomized open-label study. J Bone Miner Res. 2012;27.
209. Roux S, Bone HG, Rizzoli R, et al. Effect of denosumab on the incidence of nonvertebral fractures in postmenopausal women at increased risk of fracture: A FREEDOM study subanalysis Bone. 2010;47(Suppl 1):S213.
210. Ryder KM, Cummings SR, Palermo L, et al. Does a history of non-vertebral fracture identify women without osteoporosis for treatment? J Gen Intern Med. 2008;23(8):1177-1181.
211. Sambrook PN, Silverman SL, Cauley JA, et al. Health-related quality of life and treatment of postmenopausal osteoporosis: results from the HORIZON-PFT. Bone. 2011;48(6):1298-1304.
212. Samelson EJ, Miller PD, Christiansen C, et al. RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk. J Bone Miner Res. 2014;29(2):450-457.
213. Schneider PF, Fischer M, Allolio B, et al. Alendronate increases bone density and bone strength at the distal radius in postmenopausal women. J Bone Miner Res. 1999;14(8):1387-1393.
214. Schwartz AV, Bauer DC, Cummings SR, et al. Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: The FLEX trial. J Bone Miner Res. 2010;25(5):976-982.
215. Seeman E. The antifracture efficacy of alendronate. Int J Clin Pract. 1999(101):40-45. 216. Seeman E, Black DM, Bucci-Rechtweg C, Eastell R, Boonen S, Mesenbrink P. Zoledronic acid
substantially reduces the risk of morphometric vertebral and clinical fractures. J Clin Densitom. 2010;13:132-133.
217. Seeman E, Chapurlat R, Cheung A, et al. Risedronate reduces micro-structural deterioration of cortical bone accompanying menopause. Osteoporos Int. 2010;21(Suppl 1):S9.
218. Seeman E, Hanley D, Sellmeyer D, et al. Effects of denosumab and alendronate on skeletal microarchitecture. Bone. 2009;44(Suppl 1):S36-S37.
219. Seeman E, Libanati C, Austin M, et al. Association between transitory increase in PTH following denosumab administration and reduced intracortical porosity is a distinctive attribute of denosumab therapy. Bone. 2012(50):S162.
220. Seeman E, Libanati C, Austin M, et al. The transitory increase in PTH following denosumab administration is associated with reduced intracortical porosity: A distinctive attribute of denosumab therapy. J Bone Miner Res. 2011(26).
221. Seeman E, Libanati C, Austin M, et al. The transitory PTH increase following denosumab administration is associated with reduced intracortical porosity: A distinctive characteristic of denosumab therapy. Osteoporos Int. 2012;23:S76-S77.
22
222. Seeman E, Shane E, Thomas T, et al. Relationship between baseline remodelling intensity and changes in HR-pQCT parameters at the radius in postmenopausal women treated with denosumab or alendronate. Osteoporos Int. 2010;22(Suppl 1):S362-S363.
223. Seeman E, Thomas T, Boyd SK, et al. Effects of denosumab and alendronate at the ultradistal radius in postmenopausal women with low bone mass. Bone. 2009(44):S241.
224. Silverman S, Viswanathan H, Wang A, et al. Evaluation of health-related quality of life in postmenopausal women with osteoporosis who participated in the freedom trial. Osteoporos Int. 2010;22(Suppl 1):S14-S15.
225. Silverman S, Viswanathan HN, Yang YC, et al. Impact of clinical fractures on health-related quality of life is dependent on time of assessment since fracture: results from the FREEDOM trial. Osteoporos Int. 2012;23(4):1361-1369.
226. Simon J, Recknor C, Moffet A, et al. Effects of denosumab on radius BMD, strength, and wrist fractures: Results from the fracture reduction evaluation of denosumab in osteoporosis every 6 months (freedom) study. J Bone Miner Res. 2011;26( Suppl 1).
227. Simon JA, Recknor C, Moffett AH, et al. Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis: bone density, mass, and strength of the radius, and wrist fracture. Menopause. 2013;20(2):130-137.
228. Sone T, Kon N, Gaither KW, et al. Effects of 3-year denosumab treatment on hip structure in Japanese postmenopausal women and men with osteoporosis. Bone rep. 2017;7:164-171.
229. Sone T, Kon N, Okubo N, Fukunaga M, Ito M, Nakamura T. Effect of 3 year Denosumab Treatment on Hip Structure in Japanese Postmenopausal Women and Men with Osteoporosis. J Clin Densitom. 2018;21(4):1.
230. Sorensen OH, Crawford GM, Mulder H, et al. Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone. 2003;32(2):120-126.
231. Ste-Marie LG, Sod E, Johnson T, Chines A. Five years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis. Calcif Tissue Int. 2004;75(6):469-476.
232. Storm T, Steiniche T, Thamsborg G, Melsen F. Changes in bone histomorphometry after long-term treatment with intermittent, cyclic etidronate for postmenopausal osteoporosis. J Bone Miner Res. 1993;8(2):199-208.
233. Storm T, Thamsborg G. Long-term effect of intermittent etidronate therapy for postmenopausal osteoporosis. Osteoporos Int. 1993;Suppl 1:263.
234. Taquet AN, Clemmensen B. A three-year double-blind placebo-controlled study of risedronate in postmenopausal osteoporosis. Osteoporos-Int. 1996;Suppl 1:262.
235. Thomas T, Cheung AM, Shane E, et al. Changes in lumbar spine QCT, DXA, and TBS in postmenopausal women with low bone mass treated with denosumab, alendronate, or placebo. J Bone Miner Res. 2013(28):Conference.
236. Thomas T, Cheung AM, Shane E, et al. Changes in lumbar spine QCT, DXA and TBS following treatment with denosumab (DMAB), alendronate (ALN), or placebo (PBO) in postmenopausalwomen with low bone mass. Osteoporos Int. 2014;25:S123.
237. Tonino RP, Meunier PJ, Emkey R, et al. Skeletal benefits of alendronate: 7-Year treatment of postmenopausal osteoporotic women. J Clin Endocrinol Metab. 2000;85(9):3109-3115.
238. Torring O, Simon J, Recknor C, et al. Denosumab effects on radius BMD, estimated strength, and wrist fractures: 3-year results from the FREEDOM study. Bone. 2012;50(Suppl 1):S54-S55.
239. Tucci JR, Tonino RP, Emkey RD, Peverly CA, Kher U, Santora 2nd AC. Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. The American journal of medicine. 1996;101(5):488-501.
240. Van Der Poest CE, Patka P, Vandormael K, Haarman H, Lips P. The effect of alendronate on bone mass after distal forearm fracture. J Bone Miner Res. 2000;15(3):586-593.
241. Wasnich RD, Ross PD, Thompson DE, Cizza G, Yates AJ. Skeletal benefits of two years of alendronate treatment are similar for early postmenopausal Asian and Caucasian women. Osteoporos Int. 1999;9(5):455-460.
242. Watts NB, Brown JP, Papapoulos S, et al. Safety observations with 3 years of denosumab exposure: Comparison between subjects who received denosumab during the pivotal 3-year trial
23
and subjects who crossed over to denosumab during the extension. Arthritis and Rheumatology. 2015;67(Suppl 10).
243. Watts NB, Brown JP, Papapoulos S, et al. Safety Observations With 3 Years of Denosumab Exposure: Comparison Between Subjects Who Received Denosumab During the Randomized FREEDOM Trial and Subjects Who Crossed Over to Denosumab During the FREEDOM Extension. J Bone Miner Res. 2017;32(7):1481-1485.
244. Watts NB, Grbic JT, Binkley N, et al. Invasive Oral Procedures and Events in Postmenopausal Women With Osteoporosis Treated With Denosumab for Up to 10 Years. J Clin Endocrinol Metab. 2019;104(6):2443-2452.
245. Watts NB, Josse RG, Hamdy RC, et al. Risedronate prevents new vertebral fractures in postmenopausal women at high risk. The Journal of clinical endocrinology and metabolism. 2003;88(2):542-549.
246. Watts NB, Roux C, Modlin JF, et al. Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association? Osteoporos Int. 2012;23(1):327-337.
247. Weinstein RS, Roberson PK, Manolagas SC. Giant osteoclast formation and long-term oral bisphosphonate therapy. N Engl J Med. 2009;360(1):53-62.
248. Wustrack R, Seeman E, Bucci-Rechtweg C, Palermo L, Black D. Impact of zoledronic acid on severe vertebral fractures: Results from horizon-pivotal fracture trial. Bone. 2010;47:S194-S195.
249. Yang L, Sycheva AV, Black DM, Eastell R. Site-specific differential effects of once-yearly zoledronic acid on the hip assessed with quantitative computed tomography: results from the HORIZON Pivotal Fracture Trial. Osteoporos Int. 2013;24(1):329-338.
250. Zanchetta JR, Hoiseth A, Kendler DL, et al. Denosumab increased BMD of the lumbar spine, total hip, femoral neck, and trochanter as measured by QCT in postmenopausal women with osteoporosis. J Clin Densitom. 2010;13(1):S108.
251. Zebaze RM, Libanati C, Austin M, et al. Differing effects of denosumab and alendronate on cortical and trabecular bone. Bone. 2014;59:173-179.
252. Zebaze RM, Libanati C, McClung MR, et al. Reduced hip cortical porosity upon denosumab treatment: A likely mechanism contributing to the reduction of hip fracture risk in women with osteoporosis. Arthritis Rheum. 2013;65(Suppl 10):S370-S371.
253. Zebaze RM, Libanati C, McClung MR, et al. Reduced hip cortical porosity with denosumab (DMAB) treatment in women with osteoporosis. Ann Rheum Dis. 2014;73(Suppl 2).
254. Zhang Z, Liao EY, Wei BX, et al. Alendronate sodium/vitamin D3 combination tablet versus calcitriol for osteoporosis in Chinese postmenopausal women: A 6-month, randomized, open-label, active-comparator controlled study with a 6-month extension phase. J Bone Miner Res. 2013(28).
255. Zhang Z, Liao EY, Xia WB, et al. Effect of treatment for one yearwith alendronate/vitamin d3 combination on bone mineral density, bone biomarkers and 25(OH)D status in Chinese postmenopausal women with osteoporosis. Osteoporos Int. 2013;24:S606-S607.
256. Zhang ZL, Liao EY, Xia WB, et al. Erratum to: Alendronate sodium/vitamin D3 combination tablet versus calcitriol for osteoporosis in Chinese postmenopausal women: a 6-month, randomized, open-label, active-comparator-controlled study with a 6-month extension. Osteoporos Int. 2015;26(11):2719-2720.
257. Zhang ZL, Liao EY, Xia WB, et al. Alendronate sodium/vitamin D3 combination tablet vs. calcitriol for osteoporosis in chinese postmenopausal women: A randomized, open-label study. Osteoporos Int. 2014;25:S411.
258. Zoehrer R, Roschger P, Paschalis EP, et al. Effects of 3- and 5-year treatment with risedronate on bone mineralization density distribution in triple biopsies of the iliac crest in postmenopausal women. J Bone Miner Res. 2006;21(7):1106-1112.
24
Additional records from grey literature
Records from Clinicaltrials.gov trial registry database
Title NCT Number Link
Zoledronic Acid in the Prevention of Bone Loss in Postmenopausal Women With Osteopenia, 45 Years of Age and Older
NCT00132808 https://ClinicalTrials.gov/show/NCT00132808
A Study of Monthly Risedronate for Osteoporosis
NCT00247273 https://ClinicalTrials.gov/show/NCT00247273
Safety/Efficacy of Zoledronic Acid and Alendronate on Bone Metabolism in Postmenopausal Women With Osteoporosis
NCT00404820 https://ClinicalTrials.gov/show/NCT00404820
Alendronate Prevents Microarchitectural Deterioration of Trabecular Bone in Early Postmenopausal Women
NCT00504166 https://ClinicalTrials.gov/show/NCT00504166
Effect of Stopping Risedronate After Long Term Treatment on Bone Turnover
NCT01249261 https://ClinicalTrials.gov/show/NCT01249261
A Randomized, Double-blind, Placebo-controlled, Dose Response Study of AMG 162 (Denosumab) in Japanese Postmenopausal Osteoporotic Subjects
NCT00306189 https://ClinicalTrials.gov/show/NCT00306189
Study of the Effect of Once a Week Risedronate on the Microstructure of Tibia and Radius Using a New Scanning Method
NCT00386360 https://ClinicalTrials.gov/show/NCT00386360
A Phase II Study Evaluating SB-751689 in Post-Menopausal Women With Osteoporosis
NCT00471237 https://ClinicalTrials.gov/show/NCT00471237
Zoledronic Acid for Osteoporosis in the Elderly
NCT00558012 https://ClinicalTrials.gov/show/NCT00558012
Comparison of the Effect of an Ongoing Treatment With Alendronate or a Drug Holiday on the Fracture Risk in Osteoporotic Patients With Bisphosphonate Long Term Therapy
NCT01512446 https://ClinicalTrials.gov/show/NCT01512446
Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis
NCT01631214 https://ClinicalTrials.gov/show/NCT01631214
Denosumab China Phase III Study NCT02014467 https://ClinicalTrials.gov/show/NCT02014467
25
A Phase II/III, Double-blind, Parallel Group Comparative Study of Oral Administration of NE-58095 Tablets
NCT02063854 https://ClinicalTrials.gov/show/NCT02063854
A Double-blind Study to Assess the Efficacy and Safety of Denosumab Produced by Two Different Processes in Postmenopausal Women With Osteoporosis
NCT02157948 https://ClinicalTrials.gov/show/NCT02157948
Records from WHO-ICTRP trial registry database
Title Trial ID Link
Association between timing of zoledronic acid infusion and hip fracture healing in elderly patients.
CTRI/2019/04/018681 http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=30558
Preventing Osteoporosis in Patients with Spinal Cord Injury (SCI)
ACTRN12618000915257
http://www.anzctr.org.au/ACTRN12618000915257.aspx
Zoledronic acid in patients with low bone mass.
CTRI/2017/05/008696 http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=18914
Effect of Teriparatide, Alendronate, Zoledronic Acid, and combined effect of Teriparatide and Alendronate treatment of primary osteoporosis
IRCT201605169014N99 http://en.irct.ir/trial/9537
Osteoporosis patients after total hip replacement prosthesis research for the prevention and control of aseptic loosening
ChiCTR-ICR-15006893 http://www.chictr.org.cn/showproj.aspx?proj=11558
Zoledronate and fracture prevention in early postmenopausal women
ACTRN12612000270819
http://www.anzctr.org.au/ACTRN12612000270819.aspx
The effect of zoledronate on marrow fat in osteoporotic elderly patients who have suffered a minimal trauma fracture.
ACTRN12611000082909
http://www.anzctr.org.au/ACTRN12611000082909.aspx
To study the effects of Zoledronic acid on bone mineral density in Osteoporotic chronic spinal cord injury patients.
CTRI/2007/091/000027 http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=25
Low dose zoledronate in postmenopausal women with thin bones
ACTRN12607000576426
https://anzctr.org.au/ACTRN12607000576426.aspx
Efficacy of the anti-RANKL human antibody (Denosumab) versus Bisphosphonate for the treatment of osteoporosis in patients with primary biliary cirrhosis
JPRN-UMIN000012193 https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000014251
26
Comparative study of efficacy of minodronate, alendronate and risedronate in patients with osteoporosis
JPRN-UMIN000011407 https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000013355
A Non-inferiority Comparison of 35mg Delayed-release Risedronate, Administered Once-weekly Either Before or After Breakfast, and 5mg Immediate-release Risedronate, Administered Once-daily Before Breakfast, in the Treatment of Postmenopausal Osteoporosis as Assessed Over 2 Years; a Phase III, Multicenter, Double-Blind, Double-dummy, Randomized, Active-controlled, Parallel-group Study - Fantasia Phase III
EUCTR2007-001521-98-EE
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-001521-98
A non-invasive evaluation of bone microarchitecture modification in osteopenic postmenopausal women by 3D-peripheral quantitative computed tomography: A 24-month, monocenter, double-blind, randomized, parallel group study comparing weekly oral risedronate 35 mg and placebo
EUCTR2005-005598-30-FR
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-005598-30
A Non-invasive Evaluation of Bone Microarchitecture Modification in Osteopenic Postmenopausal Women by 3D Peripheral Quantitative Computed Tomography: A 12 Month, Multicenter, Double-blind, Randomized, Parallel Group Study Comparing Weekly Oral Risedronate 35 mg and Placebo
EUCTR2005-003033-41-GB
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-003033-41
A Phase III, Multicenter, Double-Blind, Randomized, Active-controlled, Parallel Group, Non-inferiority Study Comparing 150 mg Risedronate Monthly with 5 mg Risedronate Daily in the Treatment of Postmenopausal Osteoporosis as Assessed at 12 and 24 Months. MERIT-OP
EUCTR2005-002785-10-HU
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-002785-10
A multicentre, double-blind, randomised, active controlled, parallel group, noninferiority study comparing 75mg risedronate dosed on two consecutive days monthly with 5mg daily risedronate in the treatment of postmenopausal osteoporosis as assessed over 24 months - 2CDM
EUCTR2004-000486-35-GB
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-000486-35
27
The effect of Curcumin on Osteoporosis in Post Menopausal Women
IRCT2016030424308N1 http://en.irct.ir/trial/20548
Concise, accurate diagnosis and treatment eveluation of osteoporosis patients using new imaging techniques
ChiCTR-IPR-16009416 http://www.chictr.org.cn/showproj.aspx?proj=15990
Study to evaluate the efficacy and safety of bisphosphonates in long term treatment of osteoporosis
EUCTR2011-000290-31 https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-000290-31
The Relationship between Osteoporosis and Aortic Calcification in Postmenopausal Women
EUCTR2008-001865-28-GB
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-001865-28
A clinical trial to study the effects of denosumab drug in the treatment of postmenopausal osteoporosis
CTRI/2018/07/014908 http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=23029
Study in postmenopausal women with osteoporosis
CTRI/2018/05/013924 http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=23200
The purpose of this study is to find out more about the efficacy and safety of denosumab produced by two different processes in postmenopausal women with osteoporosis.
EUCTR2013-001279-19-CZ
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2013-001279-19
A multicenter, international, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy and safety of AMG 785 treatment in postmenopausal women with osteoporosis
per-089-12 https://www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec=089-12